retatrutide mash (40mg) MASH in Type 2 Diabetes:

this should be considered by clinicians in any trial or supervised setting, in line with NICE guideline NG28 (Type 2 diabetes in adults)

The top 3 identified otologic side effects included nasopharyngitis, sinusitis, unspecified dizziness

4 Metabolic and energy-balance peptides beyond the incretin paradigm While incretin biology has dominated metabolic drug development over the past decade, incretins represent only a subset of the endogenous peptide networks governing energy balance

Mounjaro is a branded tirzepatide product, while retatrutide is still in clinical development and not yet available as an approved pharmaceutical

It hits three receptors at once: GLP-1 (cuts appetite, slows stomach), GIP (improves insulin signaling), and glucagon (raises energy expenditure and fat mobilization)